Biosimulation Market: Introduction According to the report, the global biosimulation market was valued at US$ 1.8 Bn in 2019 and is projected to expand at a high CAGR from 2020 to 2030. Biosimulation can be defined as computer-aided mathematical simulation of biological processes, which form an integral part of the human biology system. Biosimulation is focused on offering model-based prediction of the behavior and the dynamics of biological systems. The growth of the global biosimulation market can be attributed to significant rise in spending on R&D by pharmaceutical and biotechnology companies. Additionally, high cost associated with re-conducting clinical trials, owing to the high failure rate in phase III clinical trials contributes to the adoption of biosimulation in drug discovery and drug development, which, in turn, boosts the growth of the market. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=703 North America dominated the global biosimulation market in terms of revenue in 2019 and the trend is projected to continue during the forecast period. The market in the region is anticipated to expand at a high CAGR from 2020 to 2030. The growth of the market in North America can be attributed to the strong recommendation by the U.S. FDA for adopting biosimulation, increase in adoption of predictive biosimulation in the R&D process, and rise in focus on the development of biosimulation platforms for the development of COVID-19 vaccines. Strategic Acquisitions among Key Market Players Leading players, such as Certara and Simulations Plus, focus on enhancing their market presence by adopting inorganic growth strategies. This, in turn, will enable them to cater the rise in demand and consolidate their position in the biosimulation market. Simulations Plus, a leading player in the biosimulation market acquired Lixoft of Paris, France, in April 2020. Lixoft is focused on designing software solutions for reducing the cost and increasing the success rate of new drug development. Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=703 In February 2020, Certara acquired the modelling and biosimulation technology assets from In Silico Biosciences, Inc. The assets acquired include platform of multiple integrated quantitative systems pharmacology (QSP) modules related to brain pathology and physiology. Software Dominated Global Market In terms of offering type, the software segment is projected to account for major share of the global biosimulation market during the forecast period. The growth of the segment can be attributed to increase in the number of pharmaceutical and biotechnology companies, regulatory agencies, and academic & research institutes employing biosimulation software during the research process of drug discovery and drug development. Biosimulation Market: Prominent Regions The global biosimulation market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global biosimulation